VABYSMO DIN 02554003
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Health Canada record
| Active ingredient(s) | FARICIMAB 6 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravitreal |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | S01LA09 FARICIMAB |
|---|
| Original market date | 30-Jun-2025 |
|---|
| Current status date | 30-Jun-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FARICIMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02527618 | VABYSMO | HOFFMANN-LA ROCHE LIMITED | Solution | FARICIMAB 6 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 34559 | 2024-12-13 | Supplement to a New Drug Submission (SNDS) | Addition of new presentation |
Request a quote for VABYSMO
How to read a Canadian DIN record